GHRP-6: Uses, Benefits & Research

What is GHRP-6?

GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2, MW 873.0 Da) is the first-generation growth hormone-releasing peptide, discovered in the late 1980s and extensively researched through the 1990s and 2000s. As a synthetic hexapeptide ghrelin mimetic, it stimulates GH release from the pituitary gland via the GHSR-1a receptor.

GHRP-6 is distinguished from other GHRPs by its powerful orexigenic (appetite-stimulating) effect — the strongest of any compound in this class. While this makes it less potent for pure GH release compared to GHRP-2 or Hexarelin, it creates a unique clinical niche for conditions where increasing food intake is a therapeutic priority, such as cachexia, anorexia, and catabolic states. It has a half-life of approximately 1-1.5 hours with subcutaneous bioavailability estimated at 60-70%. GHRP-6 has never received FDA approval and is WADA-prohibited since 2008.

Mechanism of Action

GHRP-6 binds directly to the GHSR-1a (ghrelin receptor) in the pituitary gland, triggering growth hormone release. As a first-generation compound, it is less selective than later GHRPs, which contributes to its broader physiological effects.

Its key distinguishing feature is the potent activation of NPY/AgRP hypothalamic neurons, producing the strongest appetite stimulation of any GHRP. In clinical studies, GHRP-6 increased food intake by 35% versus placebo — significantly more than GHRP-2 or Hexarelin. It also causes transient, dose-dependent cortisol and prolactin elevation and may stimulate endogenous ghrelin release peripherally.

GHRP-6 does not bind the CD36 cardiac receptor (unlike Hexarelin), which means it lacks the potential cardioprotective effects but also avoids the associated cardiac complexity.

Clinical Evidence

Human Studies

GHRP-6 was among the earliest GHRPs studied in humans, with research primarily from the 1990s and early 2000s. The evidence base includes 8-12 human studies and 2-4 RCTs.

First Human GH Stimulation Study (1995): Phase I RCT (N=24 healthy adults) demonstrated dose-dependent GH release with appetite increase at higher doses.

Appetite Stimulation Comparison (2001): Randomized crossover trial (N=10 healthy men) by Wren et al. showed GHRP-6 increased food intake by 35% versus placebo — the most potent orexigenic effect of any GHRP tested.

GH/IGF-1 Effects in GH-Deficient Adults: Open-label trial (N=18) using 100 mcg/kg GHRP-6 daily for 14 days showed increased GH pulses and modest IGF-1 elevation.

No active clinical trials exist as of 2026.

Preclinical Evidence

Recent preclinical work includes GHRP-6 hydrogel formulations for acute kidney injury therapy (2025), intranasal delivery studies for brain ghrelin signaling (2025), and combination therapy with epidermal growth factor in ischemic stroke models (2024). GHRP-6 derivatives have also shown atheroprotective potential via selective CD36 ligand activity.

Drug Interactions & Contraindications

Glucocorticoids are documented to blunt the GH response. Somatostatin analogs directly antagonize GHRP-6’s GH-releasing action and are contraindicated. Theoretical interactions exist with appetite suppressants (antagonistic effect), GHRH analogs (additive GH release), and IGF-1/growth hormone preparations (additive effects requiring monitoring).

GHRP-6 is contraindicated in active malignancy and pregnancy/breastfeeding. The intense appetite stimulation makes it inappropriate for obese patients where weight gain is undesirable. No formal drug interaction studies have been conducted in humans.

Safety & Side Effects

From human trials, the most notable effect is pronounced appetite increase, reported in 10% or more of subjects. Other common effects include injection site reactions, headache, transient cortisol elevation, transient prolactin elevation, and water retention (more frequent than with other GHRPs).

Theoretical concerns include unwanted weight gain from intense hunger stimulation, cancer risk from GH/IGF-1 elevation, and glucose metabolism effects in diabetic patients. No long-term (6+ month) human safety trials have been conducted.

Honest Bottom Line

GHRP-6 is a first-generation GHRP with 2-4 RCTs and the most pronounced appetite stimulation of any ghrelin mimetic. While less potent for GH release than GHRP-2 or Hexarelin, it fills a unique niche for conditions where appetite stimulation is therapeutic — cachexia, catabolic states, and situations requiring increased food intake. It has never received FDA approval, has no active clinical trials as of 2026, and remains WADA-banned. Patients considering GHRP-6 should understand they are using a Tier 3 compound with moderate human evidence and specific clinical utility for orexigenic applications.